M Klar1, A Hasenburg2, M Hasanov1, F Hilpert3, W Meier4, J Pfisterer3, E Pujade-Lauraine5, J Herrstedt6, A Reuss7, A du Bois8. 1. Department of Obstetrics and Gynecology, University Clinics of Freiburg, Freiburg, Germany. 2. Department of Obstetrics and Gynecology, University Clinics of Mainz, Mainz, Germany. Electronic address: annette.hasenburg@unimedizin-mainz.de. 3. Gynecologic Oncology Centre, Kiel, Germany. 4. Department of Obstetrics and Gynecology, University Clinics of München, München, Germany. 5. Department of Obstetrics and Gynecology, Hôpital Hôtel-Dieu, Paris, France. 6. Department of Oncology, Odense University Hospital, Odense, Denmark. 7. Coordinating Centre for Clinical Trials, University Marburg, Marburg, Germany. 8. Department of Obstetrics and Gynecology, University Clinics of München, München, Germany; Department of Gynecology and Gynecologic Oncology, Kliniken Essen Mitte, Essen, Germany.
Abstract
OBJECTIVES: We evaluated in a large study meta-database of prospectively randomised phase III trials the prognostic factors for progression-free survival (PFS) and overall survival (OS) in patients < and >40 years of age with advanced epithelial ovarian cancer. METHODS: A total of 5055 patients of the AGO, GINECO, NSGO intergroup studies AGO-OVAR 3, 5, 7 and 9 were merged to identify 294 patients <40 years and 4761 patients ≥40 years. We conducted survival analyses and Cox proportional hazard regression models and additionally analysed a very homogeneous subcohort of 405 patients with serous epithelial ovarian cancer, excellent performance status, who had received complete macroscopic upfront cytoreduction and ≥5 chemotherapy cycles. RESULTS: For patients <40 years, the median PFS was 28.9 months and the median OS was 75.3 months, while the median PFS for patients ≥40 years was 18.1 months and the median OS was 45.7 months. Independent prognostic factors were similar in both age groups. In a multivariate analysis including prognostic factors potentially leading to confounding, young age appeared to improve PFS (hazard ratio [HR], 0.86; 95% confidence interval [CI]: 0.72-1.03) and OS (HR, 0.73; 95% CI: 0.59-0.91). The observed effect was even stronger in the subcohort of optimally treated patients with SEOC: PFS (HR, 0.34; 95% CI: 0.19-0.59) and OS (HR, 0.23; 95% CI: 0.09-0.56). DISCUSSION: Prognostic factors were similar in both age groups. Young age appeared a strong independent protective prognostic factor for PFS and OS in the subcohort.
OBJECTIVES: We evaluated in a large study meta-database of prospectively randomised phase III trials the prognostic factors for progression-free survival (PFS) and overall survival (OS) in patients < and >40 years of age with advanced epithelial ovarian cancer. METHODS: A total of 5055 patients of the AGO, GINECO, NSGO intergroup studies AGO-OVAR 3, 5, 7 and 9 were merged to identify 294 patients <40 years and 4761 patients ≥40 years. We conducted survival analyses and Cox proportional hazard regression models and additionally analysed a very homogeneous subcohort of 405 patients with serous epithelial ovarian cancer, excellent performance status, who had received complete macroscopic upfront cytoreduction and ≥5 chemotherapy cycles. RESULTS: For patients <40 years, the median PFS was 28.9 months and the median OS was 75.3 months, while the median PFS for patients ≥40 years was 18.1 months and the median OS was 45.7 months. Independent prognostic factors were similar in both age groups. In a multivariate analysis including prognostic factors potentially leading to confounding, young age appeared to improve PFS (hazard ratio [HR], 0.86; 95% confidence interval [CI]: 0.72-1.03) and OS (HR, 0.73; 95% CI: 0.59-0.91). The observed effect was even stronger in the subcohort of optimally treated patients with SEOC: PFS (HR, 0.34; 95% CI: 0.19-0.59) and OS (HR, 0.23; 95% CI: 0.09-0.56). DISCUSSION: Prognostic factors were similar in both age groups. Young age appeared a strong independent protective prognostic factor for PFS and OS in the subcohort.
Authors: Andrew Bryant; Shaun Hiu; Patience T Kunonga; Ketankumar Gajjar; Dawn Craig; Luke Vale; Brett A Winter-Roach; Ahmed Elattar; Raj Naik Journal: Cochrane Database Syst Rev Date: 2022-09-26
Authors: Kehinde Sharafadeen Okunade; Adebola A Adejimi; Ephraim O Ohazurike; Omolola Salako; Benedetto Osunwusi; Muisi A Adenekan; Aloy O Ugwu; Adaiah Soibi-Harry; Olayemi Dawodu; Adeyemi A Okunowo; Rose I Anorlu; Jonathan S Berek Journal: JCO Glob Oncol Date: 2021-01